Oslo, February 27, 2026 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the second half and the full year of 2025.

Highlights

• Revenue growth: UnoMeter™ portfolio revenues of NOK 7.5 million in the second half, representing an increase of 69% from the same period in 2024. For the full year the Company recorded revenues from the UnoMeter™ portfolio of NOK 18.8 million, a growth of NOK 7.3 million / +64%.
• Successful recapitalisation: The Group raised NOK 58.5 million in gross proceeds, where NOK 50.5 million was settled in cash through private placements and a fully subscribed subsequent offering.
• Product innovation: Development of the enhanced version of UnoMeter™ Safeti™ Plus, the new UnoMeter™ Safeti™ Max, with a scheduled commercial launch in March/April 2026.The new UnoMeter™ Safeti™ Max, includes patented technology developed for Sippi®
• Portfolio expansion: Further expanding the product portfolio within the Urological drainage segment. The planned launch includes 3 new products. In combination it is estimated that the global market value of these products is at a level of NOK 1.6-1.8 billion.
• Impairment: The Group recorded an impairment loss of intangible assets related to Biim Ultrasound totaled NOK 37.7 million in H2 and NOK 41.7 million for the full year. This has no cash effect.

Subsequent events

• Strengthened liquidity position: The Group has successfully signed a loan agreement with Innovation Norway of NOK 15 million

Observe Medical invites investors, analysts, and other stakeholders to a presentation with trading update 25 March 2026, at 10:00 CET. There we will, among other, focus on our order trajectory inbound 2026, together with the conclusion from our important UnoMeter Safeti Max test that will be finalized by March 20, 2026.

The presentation will be streamed via webcast at the following link: https://qcnl.tv/p/OLaQ0Xa8KdjTtD9W3cv0PQ

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.